Dissecting the Role of Desmoplakin in Inflammation in Cardiomyopathy
剖析桥粒斑蛋白在心肌病炎症中的作用
基本信息
- 批准号:10606326
- 负责人:
- 金额:$ 4.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAdrenergic AgentsAffectArrhythmiaBiological AssayCalciumCardiacCardiac MyocytesCardiomyopathiesCell CommunicationCell DeathCell LineCellsClinicalClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesComplexCytoskeletonDNA Sequence AlterationDSPP geneDataDefectDesmosomesDevelopmentDilated CardiomyopathyDiseaseDisease ProgressionEpigenetic ProcessExposure toFibroblastsFunctional disorderFutureGap JunctionsGene ExpressionGenesGenetic TranscriptionHeartHeart DiseasesHeart failureHeterozygoteHumanImmuneImmunologicsIndividualInflammasomeInflammationInflammatoryIntercalated discIntercellular JunctionsIntermediate FilamentsInvestigationLeadLeftLeft Ventricular FunctionLeft ventricular structureLinkMacromolecular ComplexesMagnetic ResonanceMeasuresMediatingMediatorMitosisModelingMutationMyocarditisNatureNeonatalNormal CellPathologicPathologyPathway interactionsPatientsPhenotypePhosphotransferasesPositron-Emission TomographyProductionProteinsRattusRoleSeverity of illnessSignal TransductionSkinSmall Interfering RNATestingTherapeuticTissue-Specific Gene ExpressionTissuesVariantVentricularVentricular ArrhythmiaVisualizationWorkarrhythmogenic cardiomyopathycardiac tissue engineeringclinical imagingcytokinedesmoplakindifferential expressiondisorder preventioneffectiveness evaluationheart imagingheart rhythmimmune activationimmunomodulatory therapiesimmunoregulationinduced pluripotent stem cellinduced pluripotent stem cell derived cardiomyocytesinflammatory modulationinnate immune pathwaysinsightlink proteinmRNA Expressionpathogenpreventprognostic indicatorprogramsprotein expressionrecruitresponsesmall moleculestem cell modeltranscriptome sequencing
项目摘要
Project Summary/Abstract
Desmoplakin is an elongated protein that links the desmosomal components to the cytoskeleton through
intermediate filaments. Heterozygous truncation mutations in the DSP gene, which encodes desmoplakin,
cause arrhythmogenic cardiomyopathy (AC) impacting the left ventricle. A striking feature associated with
DSP truncation variants (DSPtv) is a prominent inflammatory component, and this inflammation can be well
visualized through cardiac imaging using magnetic resonance or positron emission tomography. The effect of
DSP truncations in mediating cardiac inflammation is not well understood. The nature of DSP truncations
implies that haploinsufficiency or reduction of desmoplakin protein is contributory feature of left ventricular
cardiomyopathy with inflammation. To begin to characterize the transcriptional program associated with DSP-
cardiomyopathy, I analyzed RNA-sequencing from neonatal rat ventricular cardiomyocytes with siRNA to
reduce expression of DSP. Analysis of the differentially expressed genes in siRNA-treated cardiomyocytes
identified immune chemotactic pathways as having increased expression. Of particular note were several
genes connected to pyroptosis, an immunologically active form of cell death. Taken together, these data
suggest that innate immune pathways may contribute significantly to DSP-associated cardiomyopathy. I
hypothesize that reduction of desmoplakin promotes excessive inflammasome activation in cardiomyocytes
that results in aberrant calcium handling and pro-arrhythmogenic heterocellular junctions. In Aim 1 of this
proposal, I will assess this inflammatory component of DSP-cardiomyopathy in human-induced pluripotent
stem cell (hiPSC) lines with distinct DSP truncations derived from individuals with inflammatory-arrhythmogenic
cardiomyopathy. To characterize 2D- and 3D-hiPSC models, I will assess whether DSP haploinsufficiency is
sufficient to drive expression of inflammasome components. I will then examine DSPtvs for their effects on
contractility and calcium transients in response to pathogen- and damage-derived activators of the
inflammasome. I will conduct coculture assays of hiPSC-derived cardiomyocytes and fibroblasts to evaluate
the inflammatory modulation of heterocellular junctions and cardiac conduction in DSP-cardiomyopathy. In
Aim 2 of the proposal, I will modulate innate immune activation in hiPSC-derived cardiomyocyte models using
siRNA, small molecule inhibition, and epigenetic modulation strategies. These studies will target Never in
Mitosis A-related Kinase 7 (NEK7), an inflammasome component with differential gene expression in heart
failure. The proposed studies will expand from observations in patients with DSPtvs and define the
inflammatory triggers refining the distinct pathology related to DSP-mediated disease. In particular, the
findings from this study have implications for other forms of cardiomyopathy driven by fibrotic transformation
such as dilated cardiomyopathy and heart failure.
项目总结/摘要
桥粒斑蛋白是一种延长的蛋白质,其通过连接桥粒组分与细胞骨架。
中间丝编码桥粒斑蛋白的DSP基因中的杂合截短突变,
引起影响左心室的致心肌病(AC)。一个显著的特征,
DSP截短变体(DSPtv)是一种重要的炎症组分,这种炎症可以很好地抑制。
通过使用磁共振或正电子发射断层扫描的心脏成像可视化。的影响
DSP截短介导的心脏炎症还不清楚。DSP截断的性质
提示桥粒斑蛋白单倍型不足或减少是左室肥厚的特征性表现
心肌病伴炎症。为了开始表征与DSP相关的转录程序,
心肌病,我分析了RNA测序从新生大鼠心室心肌细胞与siRNA,
减少DSP的表达。siRNA诱导心肌细胞差异表达基因的分析
鉴定免疫趋化途径具有增加的表达。特别值得注意的是,
与细胞凋亡有关的基因,细胞凋亡是一种免疫活性的细胞死亡形式。综合起来,这些数据
提示先天免疫途径可能对DSP相关性心肌病有重要作用。我
假设桥粒斑蛋白减少促进心肌细胞中过度炎性小体活化
这导致异常的钙处理和促钙离子生成的异细胞连接。目标1
建议,我将评估这一炎症组成部分的DSP心肌病在人类诱导的多能
具有不同DSP截短的hiPSC干细胞系,其来源于具有炎性-致炎性疾病的个体。
心肌病为了表征2D和3D-hiPSC模型,我将评估DSP单倍不足是否
足以驱动炎性体组分的表达。然后,我将研究DSP电视对
收缩性和钙瞬变响应病原体和损伤衍生的激活剂的
炎性小体我将进行hiPSC衍生的心肌细胞和成纤维细胞的共培养试验,以评估
DSP心肌病中异细胞连接和心脏传导的炎症调节。在
该提案的目的2,我将使用以下方法调节hiPSC衍生的心肌细胞模型中的先天免疫激活:
siRNA、小分子抑制和表观遗传调节策略。这些研究将针对Never in
有丝分裂A相关激酶7(NEK 7),一种在心脏中具有差异基因表达的炎性体组分
失败拟议的研究将从对DSPtvs患者的观察中扩展,并定义
炎性触发因子改善了与DSP介导的疾病相关的不同病理。特别是
这项研究的发现对其他形式的由纤维化转化驱动的心肌病具有启示意义
如扩张型心肌病和心力衰竭。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Selgrade其他文献
Daniel Selgrade的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 4.29万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 4.29万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 4.29万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 4.29万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 4.29万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 4.29万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 4.29万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 4.29万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 4.29万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 4.29万 - 项目类别:














{{item.name}}会员




